About PHAXIAM
PHAXIAM is a company based in Lyon (France) founded in 2004.. PHAXIAM has raised $15.8 million across 8 funding rounds from investors including AXA, Bpifrance and Idinvest Partners. PHAXIAM offers products and services including Phage Therapy and Clinical Portfolio. PHAXIAM operates in a competitive market with competitors including Gubra, Gentronix, Tigermed, Shanghai Semero Biotechnology and BioQual, among others.
- Headquarter Lyon, France
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Phaxiam Therapeutics
-
Annual Revenue
$00as on Dec 31, 2023
-
Net Profit
$-25.92 M-10524.11as on Dec 31, 2023
-
EBITDA
$-26.28 M15.84as on Dec 31, 2023
-
Total Equity Funding
$15.8 M (USD)
in 8 rounds
-
Latest Funding Round
$308.3 K (USD), Grant
Jan 01, 2020
-
Investors
AXA
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PHAXIAM
PHAXIAM offers a comprehensive portfolio of products and services, including Phage Therapy and Clinical Portfolio. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Uses bacteriophages to target and eradicate resistant bacteria effectively.
Manages phage-based solutions for severe infections through research.
Unlock access to complete
Funding Insights of PHAXIAM
PHAXIAM has successfully raised a total of $15.8M across 8 strategic funding rounds. The most recent funding activity was a Grant round of $308.3 thousand completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Grant — $308,300
-
First Round
First Round
(22 Dec 2006)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Grant - PHAXIAM | Valuation |
investors |
|
| Nov, 2018 | Amount | Grant - PHAXIAM | Valuation |
investors |
|
| Nov, 2017 | Amount | Post-IPO - PHAXIAM | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in PHAXIAM
PHAXIAM has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include AXA, Bpifrance and Idinvest Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Equity investments are provided to low and middle market companies.
|
Founded Year | Domain | Location | |
|
Karista is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location | |
|
Venture capital investments are managed by Auriga Partners in France.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by PHAXIAM
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - PHAXIAM
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Phaxiam Comparisons
Competitors of PHAXIAM
PHAXIAM operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Gubra, Gentronix, Tigermed, Shanghai Semero Biotechnology and BioQual, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Preclinical CRO services for NAFLD/NASH, diabetes, and obesity are provided.
|
|
| domain | founded_year | HQ Location |
In-vitro and in-vivo genetic toxicology screening services are provided.
|
|
| domain | founded_year | HQ Location |
Drug development and preclinical services are provided by Tigermed.
|
|
| domain | founded_year | HQ Location |
Diversified preclinical services for brain-related disorders are provided.
|
|
| domain | founded_year | HQ Location |
Contract research on infectious disease models is conducted.
|
|
| domain | founded_year | HQ Location |
Preclinical services in immunology, regeneration, neuroscience, and histology are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Phaxiam
Frequently Asked Questions about PHAXIAM
When was PHAXIAM founded?
PHAXIAM was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Where is PHAXIAM located?
PHAXIAM is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Is PHAXIAM a funded company?
PHAXIAM is a funded company, having raised a total of $15.8M across 8 funding rounds to date. The company's 1st funding round was a Post-IPO of $125M, raised on Dec 22, 2006.
What does PHAXIAM do?
PHAXIAM was founded in 2004 and is headquartered in Lyon, France, within the biopharmaceutical sector. Antibacterial therapies based on bacteriophage viruses are developed by the company to address bacterial infections in humans, particularly those resistant to conventional treatments. Operations focus on research and development of these innovative solutions. Recent activities include announcements of collaborations and research partnerships, alongside receipt of a compliance notice from Nasdaq.
Who are the top competitors of PHAXIAM?
PHAXIAM's top competitors include Gubra, BioQual and BTS Research.
What products or services does PHAXIAM offer?
PHAXIAM offers Phage Therapy and Clinical Portfolio.
Who are PHAXIAM's investors?
PHAXIAM has 6 investors. Key investors include AXA, Bpifrance, Idinvest Partners, European Union, and Karista.